Oncology Partnerships CeGaT's Twist Alliance CeGaT RNA Fusion Panel collaboration highlights strong capabilities in oncology and precision medicine, offering a clear path to co-develop and co-market targeted diagnostics with pharma and hospitals for biomarker-driven trials.

Clinical Trial Growth The introduction of a dedicated clinical trial service creates opportunities to upsell to CROs and pharmaceutical companies for trial-ready genetic analysis, patient screening, and regulatory-compliant data workflows across multi-site studies.

Broad Sequencing Capabilities Expansion into full-length 16S sequencing and Exome Xtra broadens the customer base to universities, hospitals, and biotech firms, enabling cross-sell across diagnostics, research, and translational initiatives.

Data and AI Enablement A strategic data infrastructure partnership signals readiness for large-scale genomics analytics and AI-powered insights, opening doors with enterprise customers seeking secure storage, scalable pipelines, and rapid analysis for clinical and research projects.

European Market Focus With a Germany-based footprint and mid-sized team, CeGaT is well positioned to expand with European hospitals, research centers, and CROs, leveraging oncology, infectious disease sequencing, and clinical-trial capabilities to win regional contracts.